A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2001
11/27/2001	CA2079685C Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
11/27/2001	CA2021912C Erythropoietin (epo) peptides and antibodies directed against these
11/27/2001	CA1341323C Method and composition for preventing growth and replication of cancer cells that express the core structure of a mucin-type glycoprotein
11/26/2001	CA2346163A1 Complex for transferring an anionic substance of interest into a cell
11/25/2001	CA2307128A1 Pt32 sperm protein, oocyte cytoplasmic c-yes, and uses thereof
11/22/2001	WO2001088203A1 Cloning of rhadinovirus genome and methods for its use
11/22/2001	WO2001088200A2 Isolation of genes within sle-1b taht mediate a beak in immune tolerance
11/22/2001	WO2001088138A1 Humanised antibodies to the epidermal growth factor receptor
11/22/2001	WO2001088136A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
11/22/2001	WO2001088132A2 Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
11/22/2001	WO2001088128A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/22/2001	WO2001088126A2 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
11/22/2001	WO2001088125A1 MUTATION IN THE β2 NICOTINIC ACETYLCHOLINE RECEPTOR SUBUNIT ASSOCIATED WITH NOCTURNAL FRONTAL LOBE EPILEPSY
11/22/2001	WO2001088108A1 Neuronal serine-threonine protein kinase
11/22/2001	WO2001088102A1 Method for preventing allograft rejection
11/22/2001	WO2001088097A1 Immune potentiating compositions
11/22/2001	WO2001088085A2 Novel bee venom polypeptides and methods of use thereof
11/22/2001	WO2001087981A2 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
11/22/2001	WO2001087979A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	WO2001087977A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	WO2001087939A2 Genes required for natural competence, proteins, and their use
11/22/2001	WO2001087938A2 Polynucleotide sequence encoding a putative cell adhesion molecule
11/22/2001	WO2001087937A2 G-protein coupled receptors
11/22/2001	WO2001087923A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	WO2001087350A2 Treatment of human papillomavirus (hpv)-infected cells
11/22/2001	WO2001087349A1 Carcinostatic agents or antiviral agents containing irg27 protein or gene
11/22/2001	WO2001087346A2 Dendritic cells loaded with toxic substances
11/22/2001	WO2001087339A1 Antithrombotic agents
11/22/2001	WO2001087338A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	WO2001087337A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	WO2001087336A1 Cancer treatments by using a combination of an antibody against her2 and interleukin -2
11/22/2001	WO2001087334A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	WO2001087332A1 Compositions and methods for treatment of mucosal infections
11/22/2001	WO2001087330A2 Compositions and methods for achieving immune suppression
11/22/2001	WO2001087326A1 Use of an enterobacterium ompa protein as antimicrobial agent
11/22/2001	WO2001087325A1 Method to increase class i presentation of exogenous antigens by human dendritic cells
11/22/2001	WO2001087311A1 Immunopotentiator
11/22/2001	WO2001087310A1 Process for reducing antibody response against xenografts
11/22/2001	WO2001087270A2 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
11/22/2001	WO2001087268A1 Micellar pharmaceutical compositions for buccal and pulmonary application
11/22/2001	WO2001087233A2 Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions and method of use thereof
11/22/2001	WO2001087066A1 Vaccines, immunotherapeutics and methods for using the same
11/22/2001	WO2001037862A3 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
11/22/2001	WO2001036977A3 Identification of disease markers involving mass-based-separation
11/22/2001	WO2001036476A3 Ing2, an iaps associated cell cycle protein, compositions and methods of use
11/22/2001	WO2001035995A3 Tr3-specific binding agents and methods for their use
11/22/2001	WO2001035991A3 Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
11/22/2001	WO2001034809A3 Staphylococcus epidermidis nucleic acids and proteins
11/22/2001	WO2001034805A3 Human vanilloid receptor gene
11/22/2001	WO2001034192A3 Improved method of immunization
11/22/2001	WO2001034185A3 Induction of mucosal immunity by vaccination via the skin route
11/22/2001	WO2001030989A3 Method for creating divergent populations of nucleic acid molecules and proteins
11/22/2001	WO2001030969A8 Stanniocalcin proteins and nucleic acids and methods based thereon
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001027255A3 Nucleic acid coding for a ctage gene family, use and production thereof
11/22/2001	WO2001023597A9 Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
11/22/2001	WO2001019993A3 Virulence genes of m. marinum and m. tuberculosis
11/22/2001	WO2001018169A3 Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases
11/22/2001	WO2001014564A3 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
11/22/2001	WO2001007637B1 Conditionally controlled, attenuated hiv vaccine
11/22/2001	WO2000055633A9 Methods of screening for colorectal cancer modulators
11/22/2001	WO2000010600A9 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
11/22/2001	US20010044524 Method for preparing dual virally inactivated immune globulin for intravenous administration
11/22/2001	US20010044523 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
11/22/2001	US20010044522 Polypeptides, antibodies against them and nucleic acids encoding them; detecting activated CD4+ T-cells to diagnose a disease or condition of the immune system; screening for immunosuppressants
11/22/2001	US20010044521 Especially those present in inclusion bodies in bacterial hosts, by maintaining alkaline pH in presence of chaotrophic or reducing agents, and decreasing pH gradually over given time to induce renaturation; proteomics
11/22/2001	US20010044418 Treatment of allergies
11/22/2001	US20010044416 Administering an antigen and a CD4+ T helper (Th2) cell immunostimulatory nucleic acid mucosally or dermally to produce an antigen specific immune response; treating autoimmune diseases, cancer, infections
11/22/2001	US20010044149 Transfer of heterologous gene sequences into cells using equine infectious anemia virus-derived vectors for gene delivery
11/22/2001	US20010043949 Biodegradable synthetic polymer microparticle, proteinaceous antigen and an enteric polymer which forms a coating layer on the surface of the microparticle; oral delivery of vaccine
11/22/2001	US20010043933 Exposing bacteria culture to stress, separating the medium and stress response product from the bacteria, and filtering the separated product to form a filtrate, administering the filtrate to an animal; vaccine adjuvants, treat endotoxemia
11/22/2001	US20010043932 Method of inducing cell-mediated protective immunity against HIV using low doses of immunogens
11/22/2001	US20010043931 (HRSV); Drug screening for a drug that inhibits the virus' membrane fusion machinery, such as drugs that bind the N-helix coiled-coil of HRSV and thus inhibit infection; vaccines, antibodies
11/22/2001	US20010043930 Method for treating cervical dystonia with botulinum toxin type B
11/22/2001	US20010043928 Serum preparations for inhibiting retroviruses and tumor growth
11/22/2001	US20010043914 In situ vaccination by administering to a tumor a slow-release microparticle containing Interferon-12; antigrowth, -tumor, -carcinogenic and -metastasis agents; with or without a synergistic cytokine
11/22/2001	US20010043905 Method and compositions for detection and diagnosis of infectious diseases
11/22/2001	US20010042551 Method and system for use in treating a patient with a biological substance to optimize therapy and prevent an adverse response
11/22/2001	DE10021433A1 Antiviral autovaccine, useful e.g. for treating virus-induced tumors or Crohn's disease, obtained by heating tissue containing viruses and antigens in presence of protein crosslinking agent
11/22/2001	DE10009119A1 Vertebraten Globin Vertebrate globin
11/22/2001	CA2411369A1 Antithrombotic agents
11/22/2001	CA2409813A1 Compositions and methods for treatment of mucosal infections
11/22/2001	CA2409652A1 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
11/22/2001	CA2409414A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/22/2001	CA2409361A1 Humanised antibodies to the epidermal growth factor receptor
11/22/2001	CA2409141A1 Method for preventing allograft rejection
11/22/2001	CA2409077A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
11/22/2001	CA2408974A1 Cancer treatments by using a combination of an antibody against her2 and interleukin -2
11/22/2001	CA2408830A1 Treatment of human papillomavirus (hpv)-infected cells
11/22/2001	CA2408756A1 Immune potentiating compositions
11/22/2001	CA2408691A1 Compositions and methods for achieving immune suppression
11/22/2001	CA2408617A1 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	CA2408513A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	CA2408403A1 Vaccines, immunotherapeutics and methods for using the same
11/22/2001	CA2408374A1 Mutation in the .beta.2 nicotinic acetylcholine receptor subunit associated with nocturnal frontal lobe epilepsy
11/22/2001	CA2408373A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	CA2408360A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	CA2408134A1 G-protein coupled receptors
11/22/2001	CA2407104A1 Method to increase class i presentation of exogenous antigens by human dendritic cells
11/22/2001	CA2398979A1 Novel bee venom polypeptides and methods of use thereof

1 ... 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 ... 1823